CPT 88160, in plain terms, covers A microscopic examination of cells collected from a body sample to check for abnormalities or disease. CPT 88160 is referenced in 6 tracked payer policy changes from Blue Cross NC, BlueCross BlueShield of South Carolina, and 2 other payers. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for CPT 88160 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.
Official descriptor: CPT 88160 on AAPC
Blue Cross NC issued a comprehensive medical policy update effective August 5, 2026, affecting 11 clinical policies including allergen testing, cardiovascular risk assessment, sexually transmitted infection testing, and colorectal cancer screening. Multiple billing codes were added, removed, or modified across these policies, requiring immediate system updates and billing team training to ensure accurate claim submission and avoid denials.
BlueCross BlueShield of South Carolina and BlueChoice HealthPlan updated or added medical policies in March 2026. Several code changes are effective 04/01/2026, including deletion of HCPCS G6015, G6016, C9751 and C9784, and additions of HCPCS C9810, C9817, A8005, A8006, A9294, C1607, L2221 and Q4398-Q4417, Q4420, plus CPT 0617U, 0620U, 0621U, 0628U and 0630U. CAM 126 Vitamin D Testing updates testing frequency to once per six months for symptomatic individuals who test negative at their previous test or who tested positive and began supplementation, and CAM 242 Esophageal Pathology Testing removes CPT codes 88305, 88160, 88112 and 88312.
Aetna considers breast ductal lavage medically necessary as an alternative to aspiration for diagnosing non-lactational sporadic nipple discharge when a direct nipple aspirate yields too little cellular material for adequate cytological analysis. Fiberoptic ductoscopy combined with cytology testing is medically necessary for diagnosing intra-ductal lesions in women with non-lactational sporadic nipple discharge, and as a guide for resection of known breast intra-ductal cancer. Breast ductal lavage for breast cancer screening, breast cancer risk assessment, or any other indication not listed as medically necessary, ductal endoscopy combined with lavage in the contralateral breast of women with ipsilateral breast cancer, fiberoptic ductoscopy with the Acueity System for breast cancer screening, methylation analysis of ductal lavage samples for breast cancer risk, and miRNA analysis of breast ductal fluid for detecting breast cancer are considered experimental, investigational or unproven.
Aetna considers oral brush biopsy (OralCDx Brush Test), with or without MAGE-A or GLUT-1 staining, experimental, investigational or unproven for screening, diagnosis or surveillance of cancerous or pre-cancerous oral lesions. The same designation applies to esophageal brush biopsy with WATS3D (formerly EndoCDx) for screening, diagnosis or surveillance of cancerous or pre-cancerous esophageal lesions, to DNA-image cytometry of brush biopsies for early detection of oral malignancy, to RNA-based oral brush biopsy, to salivary miRNAs as liquid biopsy biomarkers for oropharyngeal squamous cell carcinoma, and to use of an esophageal balloon for circumferential esophageal cytologic sampling. The policy lists CPT 88104 and 99000 and HCPCS D0486 and D7288 among codes not covered for the indications it lists.
EmblemHealth emphasizes cervical cancer screening as a quality measure for Cervical Health Awareness Month in January. The policy provides specific CPT and HCPCS billing codes for cervical cytology and HPV testing, along with screening timeframes and documentation requirements for women ages 21-64.
EmblemHealth emphasizes cervical cancer screening compliance during Cervical Cancer Awareness Month, specifying required screening timeframes and documentation requirements. Billing teams must use specific CPT and HCPCS codes for cervical cytology and HPV testing to ensure proper reimbursement.
Watch 88160
Get one email when a payer policy names 88160, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.
See every payer rule for 88160
Prior authorization lists, coverage criteria, NCCI edits and Medicare coverage articles for 88160 in one place.
Get alerts for changes like this
Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.